Hims & Hers Health (NYSE:HIMS) Insider Patrick Harrison Carroll Sells 23,726 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 23,726 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total value of $830,410.00. Following the completion of the transaction, the insider owned 181,861 shares of the company’s stock, valued at approximately $6,365,135. The trade was a 11.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $33.00 on Wednesday. The stock has a market capitalization of $7.64 billion, a PE ratio of -366.67, a price-to-earnings-growth ratio of 47.94 and a beta of 2.37. The business’s fifty day moving average price is $27.29 and its 200 day moving average price is $26.51. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the previous year, the firm earned $0.20 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.05 EPS for the current year.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers is expanding its GLP-1 weight-loss offering through a partnership with Novo Nordisk, which could broaden access to popular drugs like Wegovy and Ozempic and support revenue growth. Hims & Hers Health (HIMS) Expands GLP 1 Offerings With Novo Nordisk Deal And Eucalyptus Buy
• Positive Sentiment: The company also announced a new chief medical officer, Dr. Anant Vinjamoori, which may be viewed as a strengthening of its leadership team. Telehealth platform names Dr. Anant Vinjamoori as Hims CMO
• Neutral Sentiment: Analyst commentary and market articles highlighted Hims & Hers as one of several stocks that may deserve another look, but also noted that bearish price targets signal ongoing skepticism. 2 Unpopular Stocks That Deserve a Second Chance and 1 We Question
• Negative Sentiment: Insiders continued to trim holdings, with CFO Oluyemi Okupe and insider Patrick Harrison Carroll both selling shares under pre-arranged 10b5-1 plans, which can still weigh on investor sentiment. CFO insider sale filing
• Negative Sentiment: The stock also recently fell more than the broader market, reinforcing concerns that some traders may be taking profits after the recent rally. Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HIMS shares. Leerink Partners boosted their price objective on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Canaccord Genuity Group set a $32.00 price target on Hims & Hers Health in a research report on Tuesday, May 12th. Citigroup boosted their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Finally, Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $29.37.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares during the last quarter. Capital World Investors grew its stake in shares of Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after purchasing an additional 223,892 shares during the last quarter. Farallon Capital Management LLC raised its holdings in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. State Street Corp raised its holdings in shares of Hims & Hers Health by 1.8% in the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after purchasing an additional 608,950 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.